短腸症候群(SBS)的全球市場:現狀分析與預測(2021年～2027年)

全球短腸症候群(SBS)的市場規模在2021年～2025年的預測期間內，預計將以約27％的年複合成長率成長。推動市場增長的主要因素包括患者人數的增加、醫療費用的增加、由於醫療領域的快速改善而提高的認識以及促進研發。

本報告提供全球短腸症候群(SBS)市場調查，提供市場概要，市場規模和預測，趨勢，促進因素·阻礙因素，產品·流通管道·各地區的分析，及企業簡介等資訊。

目錄

第1章 市場簡介

• 市場定義
• 限制
• 相關利益者
• 報告所使用的貨幣

第2章 調查手法或前提條件

• 短腸症候群(SBS)市場調查流程
• 短腸症候群(SBS)市場調查手法
• 預測方法
• 受訪者簡介
• 短腸症候群(SBS)市場調查的主要目的

第3章 市場摘要

第4章 摘要整理

第5章 全球短腸症候群(SBS)市場上COVID-19的影響

第6章 全球短腸症候群(SBS)市場收益(2019年～2027年)

第7章 各產品的市場洞察

• 類升糖素勝肽-2(GLP2)
• 生長激素
• 麩醯胺酸
• 其他

第8章 各流通管道的市場洞察

• 醫院藥局
• 零售藥局
• 線上銷售

第9章 各地區的市場洞察

• 北美的短腸症候群(SBS)市場
  • 美國
  • 加拿大
  • 其他的北美
• 歐洲的短腸症候群(SBS)市場
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他的歐洲
• 亞太地區的短腸症候群(SBS)市場
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 其他的亞太地區
• 其他地區的短腸症候群(SBS)市場

第10章 短腸症候群(SBS)市場動態

• 推動市場要素
• 阻礙市場要素
• 影響分析

第11章 短腸症候群(SBS)市場機會

第12章 短腸症候群(SBS)市場趨勢

第13章 法律及法律規範

第14章 需求面和供給面的分析

• 需求面分析
• 供給面分析

第15章 價值鏈分析

第16章 競爭模式

• 競爭情形
  • 波特的五力分析

第17章 企業簡介

• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Zealand Pharma A/S
• OxThera
• VectivBio AG
• 9 Meters Biopharma, Inc.
• Nutrinia Ltd.
• Hanmi Pharm.Co., Ltd.
• Pharmascience, Inc.
• Nestle

第18章 免責聲明

The short bowel syndrome market is expected to register a CAGR of around 27% over the period of 2021-2027. Short bowel syndrome (SBS) is a metabolic disorder caused by dysfunction or elimination of the small intestine due to surgery for gastrointestinal disorders. The side effects of this syndrome include malabsorption, diarrhea, steatorrhea, water and electrolyte imbalances, and malnutrition. Initial treatment for short bowel syndrome includes maintaining good nutrition, maximizing the absorption area of the remaining intestine, and avoiding complications. The growing number of cases of short bowel syndrome is mainly due to an increase in diseases related to the intestine, genetic inheritance of SBS, etc. For instance, according to the National Institute of Diabetes and Digestive & Kidney Diseases, every year, short bowel syndrome affects nearly 3 out of every million people. Furthermore, the short bowel syndrome market is also anticipated to grow on account of the growing healthcare expenditure, rapid improvements in the field of healthcare have increased awareness regarding this disease, and state government with nonprofit organizations provide special incentives to market players as it promotes research & development related to short bowel syndrome.

Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc., and Nestle are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

"Amongst Product, the Glucagon-like peptide-2 (GLP2) category accounted for the majority share in the market in 2020"

Based on product, the market is classified into glucagon-like peptide- 2 (GLP2), growth hormone, glutamine, and others. Amongst products, the GLP2 category accounted for a significant share of the market. The only GLP-2 analog available on the market for the treatment of short bowel syndrome is Gattex and Revestive. the increase in prescriptions for Gattex therapy contributes to the growth of the market.

"Among Distribution Channel, the Hospital Pharmacies is expected to witness highest CAGR during the forecast period"

Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and online sales. Among these, the hospital pharmacies are expected to witness a considerable CAGR during the forecast period due to an increase in patients in hospital settings and rising implementation of therapy. Moreover, patient preference for affordable and more expensive parenteral nutrition along with prescription drugs contributes to a large share of this segment.

"North America to witness significant growth during the forecast period"

For a better understanding of the market dynamics of the short bowel syndrome market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the short bowel syndrome in 2020 owing to due to the revenue generated by Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

Global short bowel syndrome market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Short Bowel Syndrome Market
• 2.2. Research Methodology of the Short Bowel Syndrome Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Short Bowel Syndrome Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL SHORT BOWEL SYNDROME MARKET COVID-19 IMPACT

6 GLOBAL SHORT BOWEL SYNDROME MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY PRODUCT

• 7.1. Glucagon-like Peptide-2(GLP2)
• 7.2. Growth Hormone
• 7.3. Glutamine
• 7.4. Others

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Hospital Pharmacies
• 8.2. Retail Pharmacies
• 8.3. Online Sales

9 MARKET INSIGHTS BY REGION

• 9.1. North America Short Bowel Syndrome Market
  • 9.1.1. United States
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe Short Bowel Syndrome Market
  • 9.2.1. Germany
  • 9.2.2. France
  • 9.2.3. United Kingdom
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia Pacific Short Bowel Syndrome Market
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Australia
  • 9.3.5. Rest of Asia Pacific
• 9.4. Rest of World Short Bowel Syndrome Market

10 SHORT BOWEL SYNDROME MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 SHORT BOWEL SYNDROME MARKET OPPORTUNITIES

12 SHORT BOWEL SYNDROME MARKET TRENDS

13 LEGAL & REGULATORY FRAMEWORK

14 DEMAND AND SUPPLY SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porter's Five Forces Analysis

17 COMPANY PROFILED

• 17.1. Takeda Pharmaceutical Company Limited
• 17.2. Merck KGaA
• 17.3. Zealand Pharma A/S
• 17.4. OxThera
• 17.5. VectivBio AG
• 17.6. 9 Meters Biopharma, Inc.
• 17.7. Nutrinia Ltd.
• 17.8. Hanmi Pharm.Co., Ltd.
• 17.9. Pharmascience, Inc.
• 17.10. Nestle

18 DISCLAIMER